Stock NOVOGEN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Novogen Limited Other OTC

Equities

AU000000NRT0

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement
MT
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
PR
Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
CI
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
PR
Kazia Therapeutics : Appointment of Director Form 6 K
PU
Kazia Therapeutics : Securities Purchase Agreement - Form 6-K
PU
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
PR
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients
CI
Kazia Therapeutics : Purchase Agreement - Form 6-K
PU
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP
CI
Kazia Therapeutics : Corporate Presentation
PU
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K
PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
PR
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd
CI
Kazia Therapeutics : EVT801 Progress Update Presentation
PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
AQ
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study
MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KZIA Stock
  4. Stock
  5. News Novogen Limited